Ads
related to: zanubrutinib approval cll- CLL/SLL Efficacy Data
Find Data From Clinical
Trials Of A CLL/SLL Treatment
- CLL/SLL Dosing Guidelines
Get Dosing & Prescribing Info
For A CLL Treatment.
- Educational Materials
Find A Selection Of Resources To
Help Your Patients With CLL
- Patient Support Program
Offers Information & Resources Your
Patients May Need During Treatment.
- Mechanism Of Action
Learn More About Treatment-Related
Lymphocytosis In A CLL Trial
- CLL/SLL Safety Data
Find Important Safety
Information Of A CLL/SLL Treatment
- CLL/SLL Efficacy Data
Search results
Results From The WOW.Com Content Network
In January 2023, the US Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [19] In March 2024, FDA granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. [20] [21]
Acalabrutinib (Calquence), approved in October 2017 [16] for relapsed mantle cell lymphoma and in October 2019 for Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) Zanubrutinib (Brukinsa) for mantle cell lymphoma, chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). [17] It can be taken by mouth. [18] [19]
In September 2021, the FDA approved zanubrutinib to treat adults with Waldenström's macroglobulinemia, a rare non-Hodgkin lymphoma, [24] and separately granted an accelerated approval for use of the drug in the treatment of relapsed or refractory marginal zone B-cell lymphoma in patients who have been treated with an anti-CD20 regimen. [25]
For premium support please call: 800-290-4726 more ways to reach us
The company said the health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many of certain ...
Cancer is typically treated with surgery, radiation and sometimes chemotherapy. But a new study suggests this standard protocol might not be necessary for a common form of early-stage breast cancer.